Clinical Trials

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Recurrence

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

120 enrolled

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03799835 2024-12-11

ALBAN

517 enrolled

Urinary Bladder Neoplasms

NCT04806178 2024-12-09

IMMUNOBCG

30 enrolled

Urinary Bladder Neoplasms

NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Phase 3 Terminated

41 enrolled

Urinary Bladder Neoplasms

NCT02948543 2023-06-18

BCG+MM

Phase 3 Unknown

501 enrolled

Urinary Bladder Neoplasms

NCT00070070 2022-10-12

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Phase 1 Completed

6 enrolled 7 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02792192 2021-10-28

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Phase 1/2 Terminated

24 enrolled 18 charts

Urinary Bladder Neoplasms

NCT00694915 2021-08-17

STCC

122 enrolled

Urinary Bladder Neoplasms

NCT03664869 2021-04-01

FB10

Phase 3 Unknown

300 enrolled

Urinary Bladder Neoplasms, Recurrence

NCT02010203 2020-02-17

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Phase 1/2 Terminated

104 enrolled 21 charts

Urinary Bladder Neoplasms, Neoplasms

NCT01373294 2019-08-06

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

17 enrolled 8 charts

Urinary Bladder Neoplasms

NCT03790384 2018-12-31

MITOBCG

Phase 4 Unknown

140 enrolled

Phase EARLY_PHASE1 Completed

Urinary Bladder Neoplasms

NCT02326168 2017-01-25

PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

25 enrolled

Urinary Bladder Neoplasms

NCT00974818 2015-11-20

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Phase 3 Terminated

50 enrolled 7 charts

Urinary Bladder Neoplasms

NCT01498172 2015-02-04

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Phase 1 Completed

23 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Phase 3 Withdrawn

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00002490 2013-12-18

Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer

Urinary Bladder Neoplasms

NCT00002990 2013-06-12

Surgery and BCG in Treating Patients With Bladder Cancer

1,288 enrolled

Urinary Bladder Neoplasms

NCT00004122 2013-02-01

BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

Urinary Bladder Neoplasms

NCT00003759 2013-01-31

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

Urinary Bladder Neoplasms

NCT00023842 2012-09-24

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

97 enrolled

Urinary Bladder Neoplasms

NCT01442519 2011-09-28

BCG/EMDA-MMC

212 enrolled

Urinary Bladder Neoplasms

NCT00330707 2011-03-04

Combined Use of BCG and Interferon Alpha in Bladder Cancer

Phase 2/3 Completed

140 enrolled